Therapeutic cancer vaccine

Show results for

Unknown (2011)
Genomics (118)
Transcriptomics (74)
Proteomics (59)
Models (9)
Clinical (8)
Other (5)
Metabolomics (2)
Genomic (1)

Organisms

Homo sapiens (93)
Mus musculus (80)
Bos taurus (17)
Bothrops moojeni (17)
Dermestes lardarius (17)
Frangula alnus (17)
Gallus gallus (17)
Gossypium hirsutum (17)
Megathura crenulata (17)
Ovis aries (17)
Pachymenia carnosa (17)
Pandalus borealis (17)
Quercus alba (17)
Rhodotorula (17)
Senegalia senegal (17)
Medicago sativa (11)
Schistosoma mansoni (1)
Rattus rattus (1)

Organisms

Mus musculus (48)
Homo sapiens (37)
Macaca (1)

Repository

ENA (104)
geo (78)
biostudies-arrayexpress (40)
pride (21)
EGA (9)
BioModels (6)
Cell Collective (3)
iProX (2)
MassIVE (2)
MetaboLights (2)
dbGaP (1)

Tissue

Blood (6)
Bone marrow (5)
Cell culture (5)
Mononuclear cell (5)
Breast cancer cell (2)
Peripheral blood mononuclear cell (2)
Astrocyte (1)
B cell (1)
Blood cell (1)
Brain (1)
Breast (1)
Breast cancer cell line (1)
Central nervous system (1)
Colon (1)
Epithelial cell of lung (1)
Epithelial cell of skin gland (1)
Esophagus (1)
Esophagus squamous epithelium (1)
Kidney (1)
Leukocyte (1)
Lung (1)
Macrophage (1)
Neoplastic cell (1)

Disease

Acute myeloid leukemia (5)
Colorectal Neoplasms (2)
Brain cancer (2)
Brain glioblastoma multiforme (2)
Chronic lymphocytic leukemia (2)
Prostate cancer (1)
Carcinoma (1)
Melanoma (1)
Neoplasm Metastasis (1)
Neoplasms (1)
Prostate and colon cancer (1)
Prostatic Neoplasms (1)
Breast cancer (1)
Colon adenocarcinoma (1)
Gastroesophageal adenocarcinoma (1)
Lung adenocarcinoma (1)
Melanomatosis (1)

Technology Type

Mass Spectrometry (21)
Shotgun proteomics (11)
Bottom-up proteomics (4)
Immunopeptidomics (4)
Data-dependent acquisition (3)
Affinity purification coupled with mass spectrometry proteomics (2)
Mass spectrometry (1)
Mass spectrometry assay (1)
SWATH MS (1)
Top-down proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse phase (2)
Liquid Chromatography MS - positive - reverse phase (2)
Illumina NovaSeq 6000 (1)
Illumina HiSeq 2000 (1)
NextSeq 500 (1)
LTQ Orbitrap Elite (1)
Q Exactive (1)

Publication Date

2013 (25)
2015 (20)
2026 (19)
2025 (18)
2024 (15)
2021 (11)
2014 (8)
2022 (7)
2020 (6)
2023 (5)
2010 (5)
2016 (3)
2019 (2)
2012 (2)
2008 (2)
2005 (1)

UNIPROT ID/AC

C4NUM1 (1)
P70293 (1)
Q3UNK5 (1)

Metabolite Name

1-Carboxyethylleucine (1)
11Z-Octadecenylcarnitine (1)
2-Hydroxyhexadecanoylcarnitine (1)
21-Deoxycortisol (1)
24,25-Dihydroxyvitamin D (1)
25,26-dihydroxyvitamin D (1)
3-Hydroxymethylantipyrine (1)
4-Hydroxyantipyrine (1)
4-hydroxystradiol (1)
Adrenoyl ethanolamide (1)
Allopurinol (1)
Aminovaleric acid betaine (1)
Buprenorphine (1)
Calcitriol (1)
Cervonoyl ethanolamide (1)
Cortexolone (1)
Corticosterone (1)
D-Tryptophan (1)
DL-2-Aminooctanoic acid (1)
Docosapentaenoic acid (22n-3) (1)
Docosapentaenoic acid (22n-6) (1)
Eplerenone (1)
Ethotoin (1)
Fexofenadine (1)
Hepoxilin A3 (1)
Hypoxanthine (1)
Indoleacrylic acid (1)
L-Tryptophan (1)
Leukotriene B4 (1)
N-Lactoylleucine (1)

First Public Date

2026 (19)
2014 (19)
2025 (17)
2024 (12)
2015 (11)
2023 (7)
2022 (6)
2020 (5)
2019 (2)
2018 (2)
2016 (2)
2013 (2)

Modelling Approach

Ordinary differential equation model (4)

Study status

Completed (4)
Not yet recruiting (2)
Recruiting (1)
Withdrawn (1)

Lab affiliation

Institute for Research in Immunology and Cancer, Department of Biochemistry, Department of Chemistry, Université de Montréal, Québec, Canada H3T 1J4 (5)
Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany (2)
1. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Germany 3. Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Germany 4. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Germany (1)
BriaCell Therapeutics Corporation, Berkeley, CA, USA (1)
DKFZ F130 Division of Immunotherapy and Immunoprevention (1)
Department of Biological Engineering, Massachusetts Institute of Technology (1)
Department of Immunology, Interfaculty Institute for Cell Biology, Tübingen, Germany (1)
Institute for Research in Immunology and Cancer, Department of Chemistry, Université de Montréal, Montréal, Québec, Canada H3T 1J4 (1)
International Center for Cancer Vaccine Science (ICCVS), University of Gdansk, Gdansk, Poland (1)
Northwestern University (1)
Oncology-Pathology, Scilifelab, Karolinska Institutet, Stockholm, Sweden (1)
PRISM - Inserm U1192 Universite de Lille France (1)
Proteomics Center, Erasmus MC (1)
Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA 7Present address: Bristol Myers Squibb, Lawrenceville, NJ 08901, USA and Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA. (1)
Unit of Chemical Proteomics, Division of Chemistry I, Dept. of Medical Biochemistry and Biophysics (MBB), Karolnska Institutet, Biomedicum, Solna, Sweden (1)
Université de Montréal (1)

Keyword

GI cancer (2)
Nivolumab (2)
Advanced (1)
All types metastatic cancer where at least one tumor lesion is accessable for percutaneous cryoablation (1)
CTLA-4 (1)
GRT-C903 (1)
GRT-R904 (1)
Immunotherapy (1)
Ipilimumab (1)
Kidney cancer (1)
Metastatic (1)
Neoantigen cancer vaccine (1)
PD-1 (1)
Renal Cell Carcinoma (1)
Shared neoantigen (1)
Tislelizumab (1)
Vaccines (1)

IsPrivate

False (6)

Submitter Keywords

Immuno-oncology (3)

Study type

Transcription profiling by array (18)
Proteomic profiling by array (17)
Interventional (8)
Human - One-color microarray (2)
RNA-seq of coding RNA from single cells (2)
RNA-seq of coding RNA (1)

Release Date

2022 (267)
2021 (222)
2025 (204)
2023 (204)
2024 (185)
2020 (165)
2019 (114)
2018 (101)
2015 (97)
2014 (95)
2017 (88)
2016 (76)
2013 (45)
2012 (39)
2026 (38)
2010 (31)
2011 (28)
2008 (21)
2009 (17)
2006 (5)
2005 (2)
2007 (2)
2004 (2)
2001 (2)
1999 (1)

Location

United States (4)
Cuba (2)
Australia (1)
Israel (1)

Previous page
1 / 229
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 229
Next page

Sort by:

Relevance

Page size

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]

Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42163 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42175 | biostudies-arrayexpress

Therapeutic Exosomal Vaccine for Enhanced Cancer Immunotherapy by Mediating Tumor Microenvironment

PRJNA787786 | ENA

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42176 | biostudies-arrayexpress

Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]

ORGANISM(S): Homo sapiens

2013-04-01 | E-GEOD-42179 | biostudies-arrayexpress

A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

PRJNA1234707 | ENA

A Therapeutic Vaccine for Fibrolamellar Hepatocellular Carcinoma

PRJNA1234708 | ENA

Cappuccio2007 - Tumor-immune system interactions and determination of the optimal therapeutic protocol in immunotherapy

This ordinary differential equation model is the Panetta-Kirschner model of tumor-immune interactions is described in the publication: Cappuccio A, Castiglione F, Piccoli B." Determination of the optimal therapeutic protocols in cancer immunotherapy." Math Biosci. 2007 Sep;209(1):1-13. doi: 10.1016/...

2024-09-02 | BIOMD0000001036 | BioModels

Immuno-oncology

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Not available

S-EPMC4167476 | biostudies-literature

Nanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resis...

2025-03-13 | MTBLS12284 | MetaboLights

Previous page
1 / 229
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 229
Next page

Sort by:

Relevance

Page size

2287 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets